Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities.

Jiewen WangGuangbo KangHuiying LuArio de MarcoHaibin YuanZelin FengMengxue GaoXiaoli WangHuahong WangXiaolan ZhangYuli WangMiao ZhangPing WangYuanhang FengZhan Ju LiuXiaocang CaoHe Huang

Published in: Clinical and translational medicine (2024)

A bispecific nanobody (BsNb) was created to target TNF-α and IL-23p19, exhibiting high affinity and remarkable stability. BsNb-Fc inhibited the release of cytokines in CD4+T cells during co-culture experiments. BsNb-Fc effectively alleviated colitis severity in mouse model with acute colitis induced by DSS or TNBS, outperforming the IFX&UST combination.

Keyphrases

mouse model
rheumatoid arthritis
liver failure
oxidative stress
ulcerative colitis
respiratory failure
type diabetes
radiation induced
radiation therapy
hepatitis b virus
insulin resistance
wild type